Prospective Sexual Function Study for BPH Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

489

Participants

Timeline

Start Date

February 18, 2013

Primary Completion Date

April 5, 2016

Study Completion Date

April 5, 2016

Conditions
Prostatic Hyperplasia
Interventions
DRUG

Dutasteride plus tamsulosin

Take 1 capsule daily

DRUG

Placebo

Take one capsule daily

Trial Locations (67)

1032

GSK Investigational Site, Budapest

1074

GSK Investigational Site, Budapest

1204

GSK Investigational Site, Budapest

2000

GSK Investigational Site, Sydney

2031

GSK Investigational Site, Randwick

2076

GSK Investigational Site, Wahroonga

3084

GSK Investigational Site, Heidelberg

3144

GSK Investigational Site, Malvern

3526

GSK Investigational Site, Miskolc

4021

GSK Investigational Site, Kippa-Ring

4029

GSK Investigational Site, Herston

4043

GSK Investigational Site, Debrecen

4400

GSK Investigational Site, Nyíregyháza

5000

GSK Investigational Site, Adelaide

6600

GSK Investigational Site, Szentes

10787

GSK Investigational Site, Berlin

11009

GSK Investigational Site, Cadiz

11521

GSK Investigational Site, Athens

11522

GSK Investigational Site, Athens

11527

GSK Investigational Site, Athens

13600

GSK Investigational Site, Alcazar de San Juan (Ciudad Real)

14057

GSK Investigational Site, Berlin

15344

GSK Investigational Site, Strausberg

16515

GSK Investigational Site, Oranienburg

18012

GSK Investigational Site, Granada

19002

GSK Investigational Site, Guadalajara

19230

GSK Investigational Site, Hagenow

20850

GSK Investigational Site, Mendaro, Guipuzcoa

21200

GSK Investigational Site, Argos

21244

GSK Investigational Site, Buchholz

22880

GSK Investigational Site, Wedel

24143

GSK Investigational Site, Kiel

28007

GSK Investigational Site, Madrid

28031

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28822

GSK Investigational Site, Coslada

28905

GSK Investigational Site, Getafe/Madrid

29600

GSK Investigational Site, Marbella

30008

GSK Investigational Site, Murcia

30029

GSK Investigational Site, Nîmes

35039

GSK Investigational Site, Marburg

41110

GSK Investigational Site, Larissa

41930

GSK Investigational Site, Bormujo (Sevilla)

44225

GSK Investigational Site, Dortmund

44277

GSK Investigational Site, Nantes

45004

GSK Investigational Site, Toledo

45100

GSK Investigational Site, Orléans

48249

GSK Investigational Site, Dülmen

52064

GSK Investigational Site, Aachen

75651

GSK Investigational Site, Paris

79100

GSK Investigational Site, Thouars

90441

GSK Investigational Site, Nuremberg

92380

GSK Investigational Site, Garches

04109

GSK Investigational Site, Leipzig

06333

GSK Investigational Site, Hettstedt

06295

GSK Investigational Site, Eisleben Lutherstadt

115 22

GSK Investigational Site, Athens

1311RL

GSK Investigational Site, Almere Stad

6191 JW

GSK Investigational Site, Beek

7009 BL

GSK Investigational Site, Doetinchem

6716 RP

GSK Investigational Site, Ede

5623 EJ

GSK Investigational Site, Eindhoven

8601 ZK

GSK Investigational Site, Sneek

3511 NH

GSK Investigational Site, Utrecht

7101 BN

GSK Investigational Site, Winterswijk

08006

GSK Investigational Site, Barcelona

01009

GSK Investigational Site, Vitoria-Gasteiz

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01777269 - Prospective Sexual Function Study for BPH Subjects | Biotech Hunter | Biotech Hunter